Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors

• Published in: Journal of clinical oncology Vol. 32; no. 28; pp. 3103 - 3110
• Main Authors: Infante, Jeffrey R, Dees, E Claire, Olszanski, Anthony J, Dhuria, Shyeilla V, Sen, Suman, Cameron, Scott, Cohen, Roger B
• Format: Journal Article
• Language: English
• Published: United States 01-10-2014
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Biological Availability; Cytokines - secretion; Diarrhea - chemically induced; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Inhibitor of Apoptosis Proteins - adverse effects; Inhibitor of Apoptosis Proteins - pharmacokinetics; Inhibitor of Apoptosis Proteins - therapeutic use; Male; Middle Aged; Nausea - chemically induced; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Pharmaceutical Solutions; Syndrome; Tablets; Thiazoles - adverse effects; Thiazoles - pharmacokinetics; Thiazoles - therapeutic use; Treatment Outcome; Vomiting - chemically induced
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2013.52.3993

LCL161 antagonizes the function of inhibitor of apoptosis proteins (IAPs), thereby promoting cancer cell death. This first-in-human dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of LCL161 in patients with advanced solid tumors. A second part of the study assessed the relative bioavailability of a tablet versus solution formulation.
LCL161 was administered orally, once weekly, on a 21-day cycle to adult patients with advanced solid tumors by using an adaptive Bayesian logistic regression model with overdose control-guided dose escalation.
Fifty-three patients received at least one dose of LCL161 (dose range, 10 to 3,000 mg). LCL161 was well tolerated at doses up to 1,800 mg. Cytokine release syndrome (CRS) was the only dose-limiting toxicity (in three [6%] of 53 patients) and was the most common grades 3 to 4 event (in five [9%] of 53 patients). Vomiting, nausea, asthenia/fatigue, and anorexia were common but not severe. Although the MTD was not formally determined, an 1,800-mg dose was selected in compliance with the protocol for additional study, given the dose-limiting CRS at higher doses and pharmacodynamic activity at lower doses. LCL161 was rapidly absorbed, and exposure was generally increased with dose. The tablet formulation of LCL161 was better tolerated than the solution; tablet and solution formulations had similar exposures, and the solution was discontinued. No patient had an objective response. LCL161 induced degradation of cellular IAP1 protein in the blood, skin, and tumor and increased circulating cytokine levels.
The 1,800-mg dose of LCL161, administered as a single agent once weekly, in tablet formulation is the recommended dose for additional study. This combined dose and formulation was well tolerated and had significant pharmacodynamic activity, which warrants additional investigation.